Less than 3% of cataract surgery patients received the sustained-released corticosteroids. The authors argue that the price of more than $500 is an unintentional consequence of rules that require relatively high prices to meet the thresholds for the cost of the news drugs to be passed through to the Medicare program.
Izervay, which is expected to be available within the two to four weeks, will have a list price of $2,100 per vial.
Izervay, which is administered with an intravitreal injection, is expected to be available within the two to four weeks.
The researchers estimate that optimizing vision could prevent up to 100,000 prevalent cases of dementia. They call for clinical trials to test the proposition that optimizing vision would have a preventive effect on dementia.
ABBV-RGX-314 delivers a gene encoding a therapeutic antibody fragment to inhibit vascular endothelial growth factor (VEGF). Early results show it is well-tolerated and leads to improved disease.
Patients with geographic atrophy and their caregivers would benefit from support and accommodations related to managing daily life activities and social activities, as well as their mental health, Sophie J. Bakri, M.D., said during her presentation
Xdemvy is the first treatment that directly targets the mites involved in Demodex blepharitis. It is expected to be available by the end of August 2023 and will have a list price of $1,850 per prescription.
Findings reported in JAMA Ophthalmology chip away at one of the reasons for expanding optometrist scope of practice to include office-based laser procedures. But travel time is not the whole story.
Medical specialties are beginning to look at the environmental impacts of their areas of medicine. A review published in Ophthalmology homed in on cataract surgery and steps that might be taken to reduce greenhouse gas emissions associated with one of the most commonly performed surgeries.
Idiopathic multifocal choroiditis is a rare condition that typically occurs in young women with myopia. A genome-wide association study conducted by Dutch researchers identified a genetic variant that is associated with the disease and implicates dysregulation of the complement system as a possible cause.
At issue is an ongoing review of inspection results from a third-party filling company. No issues were cited in the FDA’s complete response letter about clinical efficacy or safety.
Overall, Descemet membrane endothelial keratoplasty cost less than Descemet stripping automated endothelial keratoplasty and can be done faster, according to findings reported by University of Michigan researchers.
Results reported in JAMA Ophthalmology show that about 20% of those with diabetic retinopathy have a case that could threaten their vision.
The Dry Eye Foundation reported 205 eye drops to the FDA that were not found in the FDA database.
Regulators indicated there was a lack of evidence of effectiveness and lack of clinical trials done to support the application.
The FDA has approved two novel therapies for patients with dry eye disease: Vevye (previously CyclASol) is a water-free, preservative-free solution, and Miebo, which address the excessive tear evaporation that is seen with dry eye.
Vevye (previously CyclASol) is a water-free, preservative-free solution, which allows for improved bioavailability and better efficacy on the target tissue.
Exposure to second-hand smoke may be more harmful for young children than adults because of their faster respiratory rate.
Researchers using data from prospective cohort studies identify higher levels of diglycerides and triglycerides in the blood as possibly playing an important role in the multifactorial causation of glaucoma.
Findings reported in JAMA Opthalmology show substantial decrease from 30 years ago.
Study shows the risk after COVID-19 vaccination is comparable to risk after flu and Tdap vaccine, and that the risk from COVID-19 infection is much greater.
The surface of the eye is exposed to airflow from inhaling and exhaling air. A snug fit can reduce if not eliminate the problem.
American Indian and Alaska Native had increased access to diabetes treatment services, which lowered hyperglycemia and blood lipid levels, as well as diabetic retinopathy incidence.
The discovery of a protein that determines levels of vascular endothelial growth factor-A (VEGF) could lead to new therapies for macular degeneration, diabetic retinopathy and other common causes of vision loss.
